In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones

European Journal of Ophthalmology

Volumn 20, Issue 2, 2010, Pages 300-305

  Chawla, Bhavna ^a   Agarwal, Prakashchand ^a   Tandon, Radhika ^a   Titiyal, Jeewan S ^a   Sharma, Namrata ^a   Agarwal, Tushar ^a   Nayak, Niranjan ^a   Satpathy, Gita ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bacterial keratitis isolates; Gatifloxacin; In vitro susceptibility; Moxifloxacin

Indexed keywords

CEFAZOLIN; GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ACINETOBACTER; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORNEA ULCER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INDIA; KERATITIS; KLEBSIELLA PNEUMONIAE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

EID: 77952832413     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067211002000207     Document Type: Article

References (22)

1. McLeod SD, LaBree LD, Tayyanipour R, Flowers CW, Lee PP, McDonnell PJ. The importance of initial management in the treatment of severe infectious corneal ulcers. Ophthalmology 1995; 102: 1943-1948 (Pubitemid 26004453)
2. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991; 112: 34S-47S.
3. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs. cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995; 113: 1257-1265
4. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol 1991; 112: 15S-24S.
5. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999; 106: 1313-1318
6. Chaudhry NA, Flynn HW Jr, Murray TG, Tabandeh H, Mello MO Jr, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999; 128: 509-510
7. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002; 133: 463-466 (Pubitemid 34258055)
8. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003; 136: 500-505
9. Parmar PS, Salman A, Kalavathy CM, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol 2006; 141: 282-286 (Pubitemid 43188027)
10. Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg 2006; 32: 515-518
11. Nayak N, Satpathy G. Slime production as a virulence factor in Staphylococcus epidermidis isolated from bacterial keratitis. Indian J Med Res 2000; 111: 6-10.
12. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disc method. Am J Clin Pathol 1966; 45: 493-496
13. Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients. Indian J Med Res 2008; 127: 398-402.
14. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol 1996; 121: 712-715
15. McLeod SD, DeBacker CM, Viana MAG. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology 1995; 103: 479-484
16. Deramo VA, Lai JC, Fastenberg DM, Udell IL. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006; 142: 721-726
17. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol 2001; 85: 842-847 (Pubitemid 32662086)
18. Ly CN, Pham JN, Badenoch PR, et al. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Exp Ophthalmol 2006; 34: 44-50.
19. Laspina F, Samudio M, Cibils D, et al. Epidemiological characteristics of microbiological results on patients with infectious corneal ulcers: a 13-year survey in Paraguay. Graefes Arch Clin Exp Ophthalmol 2004; 242: 204-209 (Pubitemid 38477205)
20. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol 1997; 81: 965-971 (Pubitemid 27493983)
21. Leibovitch I, Lai TF, Senarath L, Hsuan J, Selva D. Infectious keratitis in South Australia: emerging resistance to cephazolin. Eur J Ophthalmol 2005; 15: 23-26 (Pubitemid 40462725)
22. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Ophthalmology 1999; 106: 80-85